Sarah Gilbert - Vaccibody CoFounder
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Insider
Sarah Gilbert is CoFounder of Vaccibody As
| Phone | 44 1865 818 808 |
| Web | https://www.vaccitech.co.uk |
Vaccibody Management Efficiency
The company has return on total asset (ROA) of (0.152) % which means that it has lost $0.152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2329) %, meaning that it created substantial loss on money invested by shareholders. Vaccibody's management efficiency ratios could be used to measure how well Vaccibody manages its routine affairs as well as how well it operates its assets and liabilities.Vaccibody As currently holds 8.77 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Vaccibody As has a current ratio of 18.23, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Vaccibody until it has trouble settling it off, either with new capital or with free cash flow. So, Vaccibody's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vaccibody As sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vaccibody to invest in growth at high rates of return. When we think about Vaccibody's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Francesco MD | Adicet Bio | 56 | |
| David MBA | Champions Oncology | 55 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Dr MBA | Vor Biopharma | 47 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Nicole White | Assembly Biosciences | N/A | |
| Dr MBA | MediciNova | 59 | |
| David Pompliano | Revolution Medicines | N/A | |
| Bronson Crouch | Instil Bio | 51 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Mark Dudley | Instil Bio | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Timothy Moore | Instil Bio | 63 | |
Management Performance
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 |
Vaccibody As Leadership Team
Elected by the shareholders, the Vaccibody's board of directors comprises two types of representatives: Vaccibody inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaccibody. The board's role is to monitor Vaccibody's management team and ensure that shareholders' interests are well served. Vaccibody's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaccibody's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gemma Brown, Chief Officer | ||
| Bernie McDonald, Head IP | ||
| William MBA, CEO Director | ||
| Margaret MD, Chief Officer | ||
| Adrian Hill, CoFounder Advisor | ||
| Sarah Gilbert, CoFounder | ||
| Chris Ellis, Chief Officer | ||
| Graham Griffiths, Chief Officer | ||
| Thomas MD, Chief Officer | ||
| Elizabeth MBA, Head Operations |
Vaccibody Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaccibody a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Shares Owned By Insiders | 3.45 % | |||
| Shares Owned By Institutions | 49.84 % | |||
| Number Of Shares Shorted | 159.22 K | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |